glp-1 long term weight loss Agonists Drugs Market Report, 2025-2030 Ozempic and Wegovy are marketed

That practicality is part of why it has held up as a first-line option for so long

If youre working with a therapist or psychiatrist, this data gives your provider a clear picture without relying on memory alone

The most significant clinical data on retatrutide to date come from Phase 2 trials published in 2023, including a dose-ranging study published in The New England Journal of Medicine (Jastreboff et al., NEJM 2023)

That is about double what we see with tirzepatide, nearly three times better than semaglutide and 4mmHg better than the CagriSema trials

To request prior authorization for a GLP-1 medication, you and your healthcare provider must work together to submit a formal request to your insurance company